Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase III	Supportive care	Active	16 and over	Pharmaceutical / Industry	A8851009 NCT00531479

Trial Description

Summary

The combination of anidulafungin plus voriconazole may offer an improved outcome for patients treated for Invasive Aspergillosis (IA). The purpose of this study is to compare the effectiveness and safety of anidulafungin in combination with voriconazole

Eligibility Criteria

Inclusion Criteria:

• Immunocompromised state due to either 1. receipt of hematopoeitic stem cell transplantation or 2. hematologic malignancy;

• Diagnosis of possible, probable, or proven invasive aspergillosis.

Exclusion Criteria:

• Patients with aspergilloma or chronic aspergillosis

• Receipt of 4 or more days of systemic antifungal treatment for the current episode of invasive aspergillosis

• Anticipated survival of less than 5 days or Karnofsky score <=30

Trial Contact Information

Trial Lead Organizations/Sponsors

Pfizer Incorporated

Pfizer CT.gov Call Center

Study Director

Pfizer CT.gov Call Center

Ph: 1-800-718-1021

U.S.A.
California
	La Jolla
	Pfizer Investigational Site
	LaJolla
	Pfizer Investigational Site
	Oakland
	Pfizer Investigational Site
	San Diego
	Pfizer Investigational Site
Colorado
	Denver
	Pfizer Investigational Site
Florida
	Miami
	Pfizer Investigational Site
Kentucky
	Lexington
	Pfizer Investigational Site
	Louisville
	Pfizer Investigational Site
Louisiana
	Shreveport
	Pfizer Investigational Site
Michigan
	Detroit
	Pfizer Investigational Site
Minnesota
	Minneapolis
	Pfizer Investigational Site
New Jersey
	Hackensack
	Pfizer Investigational Site
New York
	Manhasset
	Pfizer Investigational Site
	New York
	Pfizer Investigational Site
Oregon
	Portland
	Pfizer Investigational Site
Virginia
	Richmond
	Pfizer Investigational Site
Washington
	Seattle
	Pfizer Investigational Site
Australia
South Australia
	Adelaide
	Pfizer Investigational Site
Austria
	Innsbruck
	Pfizer Investigational Site
Belgium
	Brugge
	Pfizer Investigational Site
	Bruxelles
	Pfizer Investigational Site
	Leuven
	Pfizer Investigational Site
	Yvoir
	Pfizer Investigational Site
Canada
	Quebec
	Pfizer Investigational Site
Alberta
	Edmonton
	Pfizer Investigational Site
Manitoba
	Winnipeg
	Pfizer Investigational Site
Ontario
	Hamilton
	Pfizer Investigational Site
Quebec
	Montreal
	Pfizer Investigational Site
France
	Creteil
	Pfizer Investigational Site
	GRENOBLE Cedex 09
	Pfizer Investigational Site
	Strasbourg
	Pfizer Investigational Site
Italy
	Genova
	Pfizer Investigational Site
	Milano
	Pfizer Investigational Site
	Pescara
	Pfizer Investigational Site
	Roma
	Pfizer Investigational Site
Netherlands
	RC Leiden
	Pfizer Investigational Site
Republic of Korea
	Seoul
	Pfizer Investigational Site
Republic of Singapore
	Singapore
	Pfizer Investigational Site
Spain
	BADALONA
	Pfizer Investigational Site
	GRANADA
	Pfizer Investigational Site
	MADRID
	Pfizer Investigational Site
	VALENCIA
	Pfizer Investigational Site
Switzerland
	Geneve 14
	Pfizer Investigational Site
	Zürich
	Pfizer Investigational Site
Thailand
	Bangkok
	Pfizer Investigational Site
Turkey
	Ankara
	Pfizer Investigational Site
United Kingdom
	London
	Pfizer Investigational Site
	Manchester
	Pfizer Investigational Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00531479
Information obtained from ClinicalTrials.gov on March 18, 2009